期刊文献+

持续性非卧床腹膜透析患者继发性甲状旁腺功能亢进相关因素分析 被引量:4

Analysis of associated factors in secondary hyperparathyroidism of continuous ambulatory peritoneal dialysis patients
原文传递
导出
摘要 目的探讨持续性非卧床腹膜透析(CAPD)患者继发性甲状旁腺功能亢进(SHPT)的患病率及相关因素。方法分析2011年7月至2012年1月在本院腹膜透析中心规律随访的CAPD患者数据库资料。所有患者根据全段甲状旁腺激素(iPTH)分为甲状旁腺功能亢进组及甲状旁腺功能非亢进组。通过Logistic回归分析SHPT的相关影响因素。结果共纳入639例患者,SHPT的患病率为46.95%。Logistic多因素回归分析结果显示,低血红蛋白、低血钙、高血磷、高碱性磷酸酶、高血肌酐、高标准化蛋白分解代谢率(nPCR)及低钙透析液是SHPT的独立影响因素。结论CAPD患者中SHPT患病率较高,钙磷代谢异常、高蛋白饮食、肾性贫血及低钙透析液是影响SHPT发生的独立因素。 Objective To study the prevalence and associated factors of secondary hyperparathyroidism (SHPT) in continuous ambulatory peritoneal dialysis (CAPD) patients. Methods A cross-section study was performed. A total of 639 eligible participants undergoing CAPD treatment more than three months in our peritoneal dialysis center from July 2011 to January 2012 were recruited in the study. All the patients were divided into SHPT group and non- SHPT group according to the intact parathyroid hormone (iPTH) level, and the associated factors of SHirr were investigated through Logistic regression analysis. Results The prevalence of SHPT was 46.95% (300/639). Logistic regression analysis demonstrated that lower hemoglobin, hypocalcemia, hyperphosphatemia, higher alkaline phosphatase, higher Scr, higher nPCR and low calcium dialysate were independent influencing factors of SHPT. Conclusions The prevalence of SHPT is quite high in CAPD patients. Abnormal calcium-phosphorus metabolism, renal anemia, high protein diet and low calium dialysate may affect the SHPT.
出处 《中华肾脏病杂志》 CAS CSCD 北大核心 2012年第12期933-936,共4页 Chinese Journal of Nephrology
关键词 腹膜透析 甲状旁腺功能亢进症 继发性 流行病学 回归分析 Peritoneal dialysis Hyperparathyroidism, secondary Epidemiology Regression analysis
  • 引文网络
  • 相关文献

参考文献14

  • 1Bjorkman M, Sorva A, Tilvis R. Parathyroid hormone as a mortality predictor in frail aged inpatients. Gerontology, 2009, 55: 601-606.
  • 2Horl WHo The clinical consequences of secondary hyperparathyroidism: focus on clinical outcomes. Nephrol Dial Transplant, 2004, 19 Suppl 5: V2-V8.
  • 3Peiris AN, YoussefD, Grant WB. Secondary hyperparathyroidism: benign bystander or culpable contributor to adverse health outcomes? South MedJ, 2012, 105: 36-42.
  • 4Potthoff SA,Janus A, Hoch H, et a1. PTH - receptors regulate norepinephrine release in human heart and kidney. Regul Pept, 2011, 171: 35-42.
  • 5Triponez F, Dosseh D, Hazzan M, et a1. Results of systematic subtotal parathyroidectomy with thymectomy for tertiary hyperparathyroidism after renal transplantation in 70 patients. Ann Chir, 2006, 131: 203-210.
  • 6Billa V, Zhong A, BargmanJ, et a1. High prevalence of hyperparathyroidism among peritoneal dialysis patients: a review of 176 patients. Perit Diallnt, 2000, 20: 315-321.
  • 7Suwan N. Secondary hyperparathyroidism and risk factors in patients undergoing peritoneal dialysis in a tertiary hospital.J Med Assoc Thai, 2011, 94 Suppl4: SIOI-SI05.
  • 8Sherrard DJ, Hercz G, Pei Y, et al. The spectrum of bone disease in end - stage renal failure-an evolving disorder. Kidney Int, 1993,43: 436-442.
  • 9Sliem H, Tawfik G, Moustafa F, et al. Relationship of associated secondary hyperparathyroidism to serum fibroblast growth factor - 23 in end stage renal disease: a case - control study. IndianJ Endocrinol Metab, 2011, 15: 105-109.
  • 10Rao DS, Shih MS, Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N EnglJ Med, 1993, 328: 171-175.

同被引文献31

  • 1Nikodimopoulou M, Liakos S. Secondary hyperparathyro-idism and target organs in chronic kidney disease [ J ].Hippokratia, 2011,15(Suppl 1):33.
  • 2Sliem H, Tawfik G, Moustafa F, et al. Relationship ofassociated secondary hyperparathyroidism to serumfibroblast growth factor-23 in end stage renal disease :A case-control study [J]. Indian J Endocrinol Metab,2011,15(3):230.
  • 3Anderson JL, Vanwoerkom RC, Horne BD, et al.Parathyroid hormone, vitamin D, renal dysfunction,and cardiovascular disease: dependent or independentrisk factors [J]? Am Heart J, 2011, 162(2) : 331.
  • 4Buizert PJ, van Schoor NM,Simsek S,et al. PTH : anew target in arteriosclerosis? [J]. J Clin EndocrinolMetab, 2013,98(10):1583.
  • 5Komaba H, Taniguchi M, Wada A, et al.Parathyroidectomy and survival among Japanesehemodialysispatientswithsecondaryhyperparathyroidism [J]. Kidney Int, 2015 , 88(2):350.
  • 6Wannamethee SG, Welsh P, Papacosta 0, et al.Elevated parathyroid hormone, but not vitamin Ddeficiency, is associated with increased risk of heartfailure in older men with and without cardiovasculardisease [J]. Circ Heart Fail,2014,7(5):732.
  • 7Chou FF, Chen JB, Hsieh KC, et al. Cognitive changes after parathyroidectomy in patients with secondary hyperparathy- roidism[J]. Surgery, 2008, 143(4): 526-532.
  • 8Papageorgiou SG, Christou Y, Kontaxis T, et al. Dementia as presenting symptom of primary hyperparathyroidism: favoura- ble outcome after surgery[J]. Clin Neurol Neurosurg, 2008, 110(10) 1038-1040.
  • 9Matuszkiewicz-Rowiflska J. KDIGO clinical practice guidelines for the diagnosis, evaluation, prevention, and treatment of mineral and bone disorders in chronic kidney disease[J]. Pol Arch Med Wewn, 2010, 120(7-8) :300-306.
  • 10Kalirao P, Pederson S, Foley RN, et al. Cognitive impairment in peritoneal dialysis patients[J]. Am J Kidney Dis, 2011, 57 (4) : 612-620.

引证文献4

二级引证文献5

;
使用帮助 返回顶部